about company

for investors

research & development

intellectual property

contacts

česky

Azacycles nanobots hydrophilic nanoparticles

cancer stem cell therapy

nano-medicine and nano-therapy

Azacycles nanobots hydrophilic nanoparticles

The company was founded in 2003 for the purpose of research and development of new therapies for the treatment of specific and hitherto incurable forms of leukaemia with a clear vision of future production. In 2005 the company obtained a grant from the Tandem Programme of the provider the Ministry of Industry and Trade of the Czech Republic and the total volume of the project was 3.36 mil. EUR. The project was successfully completed in 2009 by opposing proceedings. Clinical tests of the first and second phase of the project’s output were conducted in years 2005 – 2009 at the Haematology Centre General Hospital University Trust in Southampton, Great Britain with excellent results. Multicenter studies are currently taking place under the coordination of the centre’s Dr. Kim Orchard. The solution of the project culminated in a series of national and European patent applications.

From year 2009 the company is engaged in production, research and development of the first generation of nanobots based on high-hydrophilic nanoparticles with ability to control liberation of included biologically active compound(s) and with full biodegradability of the nanoparticle skeletons into biologically locally native compounds. The crucial concern is in future therapy of cancer stem cells and their metastasis. The main present scope is in therapy of pancreatic tumor cancer stem cells and their metastasis and also in some leukemia diseases.

OUR JUDICIAL PRECEDENTS

HISTORY OF OUR MANUFACTURING PLANT

NANOBOT SIG MEMBERSHIP

THE ROAD MAP OF R&D

Nanobot SIG

© 2012 Azacycles s.r.o.